Study of MicroRNA192 as an Early Marker of Nephropathy in Type 2 Diabetic Patients

Abstract

Background: MicroRNAs (miRNAs) are endogenous ubiquitous non-coding single-stranded (ss) RNA transcripts, frequently of 19–25 nucleotides in length. They alter the differentiation, growth, apoptosis and proliferation of cells by interfering with protein synthesis by either inducing mRNA degradation or repressing translation. miRNAs are expressed in many diseases and different cancers such as diabetes and have the potential to become new kinds of diagnostic markers. miRNA-192 is highly expressed in kidney especially in renal cortex. Many studies have confirmed that miRNA-192 played important roles in the fibrosis of kidney and liver.
Objective: This study aimed to evaluate the use of microRNA-192 as early predictor in cases of diabetic nephropathy.
Patients and methods: This study was conducted on volunteers from Internal Medicine Department - Suez Canal Authority Hospitals. 80 subjects were divided into: 60 patients with type 2 diabetes mellitus (T2DM) who were further subdivided into (normal albuminuria group (n= 20), microalbuminuria group (n= 20), and macroalbuminuria group (n=20)), and 20 healthy control group. MicroRNA-192 was quantified in blood using Reverse Transcription TaqMan MicroRNA Assay.
Results: There was a statistical significance decrease in micro RNA-192 level in macro-albuminuria group comparedto other groups and also in microalbuminuria group compared to normal albuminuria group and healthy control group.
Conclusions: We concluded that there is a possible role of miRNA-192 in the pathogenesis and progression of diabetic kidney disease in humans. Also, blood miRNA-192 may be a useful biomarker for predicting the development and the stage of diabetic kidney disease.